Amr R. Ibrahim

Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

David Marín, Amr R. Ibrahim, Claire Lucas et al. · Journal of Clinical Oncology · 2011 · 474 citations · Full text

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley et al. · Blood · 2011 · 314 citations · Full text

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Dragana Milojković, Jane F. Apperley, Gareth Gerrard et al. · Blood · 2011 · 75 citations · Full text

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Amr R. Ibrahim, Christos Paliompeis, Marco Bua et al. · Blood · 2010 · 72 citations · Full text

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Amr R. Ibrahim, Dragana Milojković, Marco Bua et al. · Blood · 2010 · 22 citations